J-Pharma (520A) Earnings Report: Net Loss of 561 Million Yen

J-Pharma (520A) has released its financial results, reporting an operating loss of 570 million yen, ordinary loss of 564 million yen, and a net loss of 561 million yen, with basic earnings per share (EPS) of -31.22 yen. These figures reflect the upfront investments typical of a research and development-focused pharmaceutical company. On the financial front, the company holds 4.45 billion yen in cash and cash equivalents, while posting an ROE of -60.67%, an ROA of -51.80%, and a reference calculation of operating profit or loss plus depreciation and amortization for April–June 2026 of approximately -570 million yen. Operating cash flow and free cash flow both stand at -2.25 billion yen, highlighting that future pipeline progress and profitability improvement remain key areas of focus for investors.

---

Correction (September 19, 2026)：The affected figures and reporting-period labels were corrected after checking the source disclosure. Source disclosure